Cleanfarms Launches New Pilot Program to Help Fraser Valley Farmers Recycle Ag Plastics
LETHBRIDGE, Alberta, May 29, 2025 (GLOBE NEWSWIRE) -- Cleanfarms, in collaboration with the Fraser Valley Regional District (FVRD) and the British Columbia Ministry of Agriculture and Food, is launching a five-year pilot program (2025-2029) to support farmers in the Fraser Valley in recycling bale wrap and silage plastics.
This pilot builds on experience from pilots in Northern BC and expands on the work of farmers in Agassiz who have been recycling plastics for several years, recently with expertise and logistical support from Cleanfarms and financial support from the Dairy Farmers of Canada. It aims to reduce ag plastic waste while improving on-farm recycling efficiency.
Leveraging experience in preparation and collection of agricultural plastics for recycling, Cleanfarms is launching this pilot to develop sustainable long-term solutions relevant to BC agriculture. As BC's largest dairy region, the Fraser Valley pilot will provide valuable learnings to inform programming for farmers across the province.
'With upwards of $188,000 in funding, this investment aims to reduce on-farm plastic waste and lay the groundwork for a province-wide agricultural plastics recycling program. It's a crucial step toward a more sustainable and circular agricultural sector in BC.' said Jake Turek, Waste Management Engineer, British Columbia Ministry of Agriculture and Food.
'The FVRD is proud to be involved in the new five-year pilot program of collecting and recycling used agricultural plastic,' said Patricia Ross, FVRD Board Chair. 'The collaboration with Cleanfarms is creating an opportunity with practical solutions to help farmers reduce their environmental footprint in the region,' she said.
Cleanfarms will host a demonstration day in Agassiz on June 17th, 2025, where farmers can test different compactors and learn about how to participate in this pilot project. Farmers will store baled plastics on their farms, and drop-off events will be held twice per year. Additional details are available on our BC pilot web page.
'Pilot projects like this allow us to test and refine programs, making it easier to establish permanent recycling solutions,' said Barry Friesen, Executive Director. Furthermore, farmers can recycle other ag plastics through Cleanfarms' existing collection programs for used ag plastic containers, totes, drums, and Unwanted Pesticides & Livestock Medications (UPLM) which has its next collection in BC's Peace Region in 2025.
For more information on how to participate in this pilot, visit our BC Pilot webpage, or contact Carly Fraser at fraserc@cleanfarms.ca.
About CleanfarmsCleanfarms is an agricultural industry stewardship organization that contributes to a healthier environment and a sustainable future by recovering and recycling agricultural and related industry plastics, packaging and products. It is funded by its members in the crop protection, seed, fertilizer, animal health medication, peat moss, animal bedding, feed, ag plastics, and maple tubing industries. Its team members are located in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec and the Maritimes.
Media Contact Margot Beverley, Director Communications | 647-557-1801 | beverleym@cleanfarms.ca
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c317ff59-5ee7-40e8-b163-5c8a7f468bc8
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
38 minutes ago
- Business Upturn
Freeman Quantitative Trading (FQAI) 5.0 Concludes Strategic Selection in Europe
Seattle, WA , Aug. 06, 2025 (GLOBE NEWSWIRE) — Freeman Quantitative Trading (FQAI) 5.0 has successfully concluded its European strategic selection initiative, marking a major step in the platform's regional expansion and community-based development model. The process sets the foundation for deeper adoption of FQAI 5.0's AI-powered quantitative trading tools across key European markets. Spanning several months, the selection process invited participation from multiple strategy teams competing through live strategy testing, educational content, and investor community engagement. Thousands of users across Germany, France, the Netherlands, Switzerland, and beyond joined the event, highlighting growing interest in AI-managed investment platforms. This initiative was designed not only to identify local strategic direction but also to promote inclusive investor education. Through open teaching, real-time interaction, and collaborative testing, users gained practical exposure to algorithmic investing and quantitative logic—lowering the barrier to entry for individuals new to the field. Freeman Quantitative Trading emphasized that FQAI 5.0 is more than a tool—it is a scalable ecosystem. The system combines AI modeling, big data analytics, and dynamic risk control, delivering institutional-grade capabilities through fully automated workflows. With the support of regional strategy teams selected through this initiative, the platform aims to localize deployment, enhance user experience, and tailor features to the unique needs of European investors. The strategic framework now in place will guide the implementation of educational initiatives, community-driven updates, and region-specific AI strategy modules. Upcoming releases include AI-managed trading, smart stop-loss/take-profit tools, and customizable strategy switching options—all designed to improve user control, transparency, and long-term portfolio performance. Marcus Ellington, Director of Strategic Development at Freeman Quantitative Trading, stated: 'This program reflects our vision to bridge advanced AI with inclusive financial services. Europe is a key part of our global roadmap, and we are committed to building a localized, transparent, and collaborative investing environment.' As AI continues to reshape global finance, Freeman Quantitative Trading (FQAI) 5.0 is positioned to lead the way in combining automation, risk intelligence, and investor education. The success of this strategic initiative confirms the demand for accessible, intelligent tools that empower users to navigate complex markets with confidence. About Freeman Quantitative Trading: Freeman Quantitative Trading is a leading European fintech platform specializing in AI-powered quantitative investment solutions. Its flagship system, FQAI 5.0, integrates nine core trading strategies—including trend-following, statistical arbitrage, and sentiment-driven models—into an automated, user-friendly platform. With a mission to democratize intelligent finance, Freeman combines advanced technology with investor education to make data-driven trading accessible to all. Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
38 minutes ago
- Business Upturn
Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029
Boston, Aug. 06, 2025 (GLOBE NEWSWIRE) — As global demand for aesthetic enhancement rises, medical aesthetic devices are transforming how patients approach cosmetic care. From laser-based treatments to minimally invasive procedures, leading companies such as AbbVie, Alma Lasers, and Johnson & Johnson to invest in next-generation technologies to meet patient expectations for precision, safety, and recovery time. According to the report, the growing adoption of non-invasive techniques, rapid advances in cosmetic laser systems, and the rise in medical tourism are redefining treatment standards. The global market is projected to grow at a CAGR of 11.3% from 2024 to 2029. As North America maintains its leadership and Europe rapidly scales access to aesthetic treatments, manufacturers must navigate strict regulatory frameworks, ensure clinical efficacy, and address affordability to realize the sector's full potential. Market Overview: Key Insights and Forecast BCC Research's latest report, Medical Aesthetic Devices: Technologies and Global Markets, offers a comprehensive assessment of the evolving aesthetics landscape. It explores innovations across laser systems, breast implants, body contouring tools, and injectables, while also examining demand trends by age group, geographic region, and treatment type. The global market for medical aesthetic devices was valued at $20.1 billion in 2023 and is projected to reach $37.9 billion by the end of 2029. The report delivers forward-looking insights based on past sales trends, device approvals, clinical trial momentum, and regional adoption patterns. It segments the market by device type, application, and end user, supported by data- intensive analysis of market size, product strategies, and regional shifts. Market Leadership in Transition The competitive landscape is evolving as companies scale energy and non-energy-based devices to support dermatological, surgical, and body contouring applications. Non-energy-based aesthetic devices—such as breast implants and dermal fillers—are expected to dominate the market by value through 2029. Companies such as Bausch Health Companies, Merz Pharma, and S.p.A. are advancing proprietary solutions aimed at scar reduction, wrinkle treatment, and facial rejuvenation. These companies are expanding regionally and leveraging partnerships for clinical validation and faster approvals (Chapter 7: Competitive Intelligence). Emerging Technologies and Investment Trends Technology is pushing the boundaries of aesthetic medicine. Robotic-assisted procedures, AI-guided skin diagnostics, and plasma-based skin therapies are expanding the range of possibilities for clinicians and patients alike. Startups such as Nova Plasma Ltd. and InMode are entering the field with breakthrough platforms targeting both safety and personalization. These shifts are driving fresh investments and accelerating product development cycles—particularly in light-based therapies and microfocused ultrasound applications (Chapter 5: Emerging Technologies and Developments). Pipeline Assessment and Applications Device manufacturers are investing heavily in next-gen solutions that blur the lines between cosmetic and therapeutic care. Procedures such as non-surgical body contouring and RF microneedling are expanding beyond traditional beauty centers and entering mainstream healthcare environments. Procedures for anti-aging, facial sculpting, and skin resurfacing are leading R&D investment, with a strong pipeline of multi-modal platforms that offer real-time feedback and adaptable energy delivery (Chapter 6: Market Segmentation Analysis). Regulatory and Access Challenges Regulatory bodies in the U.S., EU, and Asia are tightening controls around efficacy claims, clinical performance, and safety data. From FDA approvals to CE mark certifications, device manufacturers must maintain ongoing compliance for sustained market presence. Countries such as Japan, China, and Saudi Arabia are building tailored frameworks to govern the fast-evolving aesthetics space. Meanwhile, fragmented reimbursement policies and variable access in emerging economies continue to challenge equitable adoption (Chapter 4: Industry Outlook: Regulatory Framework). Strategic Outlook: The Road Ahead As the medical aesthetics field evolves, manufacturers are intensifying efforts to enhance procedural precision, minimize recovery time, and offer patient-specific outcomes. This includes innovations in ergonomic device design, non-invasive treatment delivery, and seamless clinical workflow integration (Chapter 7: Competitive Intelligence). In parallel, sustainability efforts are gaining traction across the value chain. From reduced material waste, greener energy consumption, and lifecycle-conscious device design to energy-efficient R&D practices, these priorities are increasingly being embedded into product development and procurement strategies. Firms aligning innovation with ESG values are better positioned to lead the next wave of responsible growth (Chapter 9: Sustainability in the Medical Aesthetic Device Industry; Chapter 7: Competitive Intelligence). Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $20.1 billion Market size forecast $37.9 billion Growth rate CAGR of 11.3% for the forecast period of 2024-2029 Segments covered Device Type, Application, End User, and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Countries covered U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Japan, China, India, South Korea, Australia Market drivers Adoption of minimally-invasive devices. Increase in medical aesthetic procedures. Developments in cosmetic surgery using laser technology. Rise in prevalence of obesity. Rise in medical tourism. Increase in demand for breast augmentation surgeries. Additional Insights: Global demand for medical aesthetic and cosmetic surgery procedures remains strong, with the U.S., Brazil, Japan, Italy, and Mexico the top five countries for total procedures performed. In 2023, the total number of surgical and non-surgical aesthetic procedures increased by 3.4%, reaching approximately 34.9 million worldwide . Breast augmentation continues to lead as the most commonly performed cosmetic surgery, accounting for 16.0% of all surgical procedures, followed by liposuction (15.1%), eyelid surgery (12.1%), rhinoplasty (8.4%), and abdominoplasty (7.6%). Women account for nearly 85.5% of all surgical cosmetic procedures performed worldwide. Market leaders include: AbbVie Inc. Alma Lasers Bausch Health Companies Inc. Candela Corp. Cutera Inc. Cynosure Lutronic Spa Implantech Johnson & Johnson Lumenis Be Ltd. Medytox Merz Pharma Photomedex Tiger Biosciences Venus Concept Get your copy of the report directly from BCC Research. To request more information or complete your purchase, connect with us at [email protected]. About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email [email protected] or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
38 minutes ago
- Business Upturn
Global Myeloproliferative Disorder Treatment Market is Expected to Showcase an Incremental Growth at a CAGR of ~5% by 2032
New York, USA, Aug. 06, 2025 (GLOBE NEWSWIRE) — Global Myeloproliferative Disorder Treatment Market is Expected to Showcase an Incremental Growth at a CAGR of ~5% by 2032 | DelveInsight The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's robust growth potential. Chief among these is the growing incidence of MPDs, largely attributed to an aging global population, greater awareness of the disease, and enhanced diagnostic tools. Additionally, breakthroughs in molecular diagnostics and the emergence of targeted therapies have transformed the treatment landscape, allowing for earlier diagnosis, more accurate treatment strategies, and better patient outcomes. DelveInsight's Myeloproliferative Disorder Treatment Market Insights report provides the current and forecast market analysis, individual leading myeloproliferative disorder treatment companies' market shares, challenges, myeloproliferative disorder treatment market drivers, barriers, trends, and key market myeloproliferative disorder treatment companies in the market. Key Takeaways from the Myeloproliferative Disorder Treatment Market Report As per DelveInsight estimates, North America is anticipated to dominate the global myeloproliferative disorder treatment market during the forecast period. In the drug class segment of the myeloproliferative disorder treatment market, the JAK inhibitors (JAKis) category accounted for the largest market share in 2024. Notable myeloproliferative disorder treatment companies such as Novartis AG, Incyte Corporation, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia, Shire, Pfizer, Takeda, Teva Pharmaceuticals, Merck, and several others are currently operating in the myeloproliferative disorder treatment market. and several others are currently operating in the myeloproliferative disorder treatment market. In September 2023, GSK announced that the U.S. Food and Drug Administration (FDA) approved OJJAARA (momelotinib) for the treatment of adults with intermediate or high-risk myelofibrosis, including both primary myelofibrosis and secondary forms arising from polycythaemia vera or essential thrombocythaemia, who also have anaemia. To read more about the latest highlights related to the myeloproliferative disorder treatment market, get a snapshot of the key highlights entailed in the Global Myeloproliferative Disorder Treatment Market Report Myeloproliferative Disorder Treatment Overview Myeloproliferative disorders are a group of rare blood cancers characterized by the abnormal production of blood cells in the bone marrow. Treatment approaches for MPDs primarily focus on controlling symptoms, reducing the risk of complications such as thrombosis, and slowing disease progression. Therapies may include medications like hydroxyurea or interferon-alpha to suppress overactive bone marrow function, and low-dose aspirin to reduce clotting risks. In patients with polycythemia vera or essential thrombocythemia, therapeutic phlebotomy or platelet-lowering agents may also be employed to maintain optimal blood counts. More advanced or high-risk cases, such as those progressing to myelofibrosis or acute leukemia, may require targeted therapies like JAK inhibitors, which help manage symptoms like splenomegaly and constitutional complaints. In selected younger or high-risk patients, allogeneic stem cell transplantation remains the only potentially curative option, though it carries significant risks. Supportive care, including blood transfusions and management of anemia or bleeding, is also essential to improve patient quality of life. Treatment is usually individualized based on disease subtype, risk stratification, and patient-specific factors such as age and comorbidities. Myeloproliferative Disorder Treatment Market Insights North America dominated the myeloproliferative disorder treatment market in 2024. This leadership is largely due to the high incidence of disorders like polycythemia vera, essential thrombocythemia, and myelofibrosis, along with widespread awareness of these conditions among both healthcare professionals and patients. The region also benefits from active research and development efforts and frequent product launches by leading companies in the myeloproliferative disorder space. The chronic nature of chronic myeloid leukemia and related neoplasms necessitates continuous treatment and monitoring, boosting the adoption of targeted therapies. Given the rarity of these disorders among younger populations, the emphasis is on adult and elderly patient care, which is supported by improvements in diagnostic tools and therapeutic approaches. Further driving market expansion are new product introductions by major industry players. A significant example is the FDA's approval of OJJAARA (momelotinib) in September 2023. Developed by GSK plc, Ojjaara is indicated for adults with intermediate- or high-risk myelofibrosis, including both primary and secondary forms (post-PV or post-ET), particularly in patients with anemia. This once-daily oral therapy is a JAK1/JAK2 and ACVR1 inhibitor, offering a unique mechanism of action that targets both the disease and anemia symptoms. Taken together, these factors are expected to significantly propel the growth of the myeloproliferative disorder treatment market in North America from 2025 through 2032. To know more about why North America is leading the market growth in the myeloproliferative disorder treatment market, get a snapshot of the Myeloproliferative Disorder Treatment Market Outlook Myeloproliferative Disorder Treatment Market Dynamics The myeloproliferative disorder treatment market is shaped by a complex interplay of clinical, regulatory, and commercial factors. MPDs, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are chronic hematological malignancies characterized by abnormal proliferation of blood cells. The market is witnessing steady growth due to the increasing prevalence of these disorders globally, especially among the aging population. Rising awareness among healthcare professionals and patients has led to improved diagnosis rates, which in turn is driving demand for effective treatment options. A major dynamic influencing the market is the advancement in targeted therapies and biologics. JAK inhibitors, particularly ruxolitinib and fedratinib, have become central to MPD management, especially for myelofibrosis. These therapies have shown significant efficacy in symptom control and spleen size reduction. However, unmet needs remain, especially in patients who are refractory to JAK inhibitors or who experience adverse events, prompting ongoing research into novel agents, including BET inhibitors, telomerase inhibitors, and combination regimens. Pharmaceutical companies are investing heavily in R&D to diversify and strengthen their MPD pipelines. Regulatory support and accelerated drug approvals have also played a pivotal role in shaping the treatment landscape. Several orphan drug designations and fast-track approvals have encouraged innovation in this niche segment. Additionally, strategic collaborations between biotech firms and large pharmaceutical companies are fueling the development and commercialization of advanced therapeutics. However, the high cost of novel treatments and limited access in low- and middle-income countries remain critical challenges, potentially hampering equitable market growth. Another key factor is the expansion of diagnostic capabilities and companion diagnostics. As precision medicine gains ground, genetic and molecular profiling of MPD patients is increasingly guiding treatment decisions. This trend supports the uptake of targeted therapies but also necessitates sophisticated diagnostic infrastructure, which is unevenly distributed across regions. North America dominates the market due to its robust healthcare infrastructure, higher awareness levels, and favorable reimbursement policies, while Asia-Pacific is expected to exhibit the fastest growth due to rising healthcare investments and expanding patient populations. Lastly, the MPD treatment market is characterized by a relatively slow patient turnover and chronic disease progression, which influences long-term drug adherence and revenue models. While current therapies focus on symptom control and disease stabilization, curative treatments are still elusive. This underscores the importance of continuous innovation and the development of disease-modifying agents. As the understanding of MPD pathophysiology deepens and new targets are identified, the market is poised for transformation with the potential emergence of next-generation therapies that could significantly alter disease outcomes. Get a sneak peek at the myeloproliferative disorder treatment market dynamics @ Myeloproliferative Disorder Treatment Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Myeloproliferative Disorder Treatment Market CAGR ~5% Key Myeloproliferative Disorder Treatment Companies Novartis AG, Incyte Corporation, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia, Shire, Pfizer, Takeda, Teva Pharmaceuticals, Merck, and others Myeloproliferative Disorder Treatment Market Assessment Myeloproliferative Disorder Treatment Market Segmentation Myeloproliferative Disorder Treatment Market Segmentation By Drug Class: Inhibitors (JAK Inhibitors, Tyrosine Kinase Inhibitors, STAMP Inhibitor, and Protein Synthesis Inhibitor), and Interferons Myeloproliferative Disorder Treatment Market Segmentation By Treatment Type: Targeted Therapy, Immunotherapy, and Chemotherapy Myeloproliferative Disorder Treatment Market Segmentation By Indication: Chronic Myeloid Leukemia (CML), Polycythemia Vera, Myelofibrosis, and Essential Thrombocythemia (ET) Myeloproliferative Disorder Treatment Market Segmentation By Route of Administration: Oral and Subcutaneous Myeloproliferative Disorder Treatment Market Segmentation By Distribution Channel: Retail & Hospital Pharmacies and Online Pharmacies Myeloproliferative Disorder Treatment Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the myeloproliferative disorder treatment market are set to emerge as the trendsetter explore @ Myeloproliferative Disorder Treatment Analysis Table of Contents 1 Myeloproliferative Disorder Treatment Market Report Introduction 2 Myeloproliferative Disorder Treatment Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Myeloproliferative Disorder Treatment Market Key Factors Analysis 6 Myeloproliferative Disorder Treatment Market Porter's Five Forces Analysis 7 Myeloproliferative Disorder Treatment Market Layout 8 Myeloproliferative Disorder Treatment Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the myeloproliferative disorder treatment market by 2032? Click to get a snapshot of the Myeloproliferative Disorder Treatment Market Analysis Related Reports JAK Inhibitors Market JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others. Polycythemia Vera Market Polycythemia Vera Market Insight, Epidemiology and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key polycythemia vera companies, including Incyte, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience, Disc Medicine, GluBio Therapeutics, among others. Myelofibrosis Market Myelofibrosis Market Insight, Epidemiology and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key myelofibrosis companies, including Novartis AG, Incyte Corporation, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia, Shire, Pfizer, Takeda, Teva Pharmaceuticals, Merck, among others. Chronic Myelocytic Leukemia Market Chronic Myelocytic Leukemia Market Insight, Epidemiology and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CML companies, including Novarits Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc., Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, among others. Essential Thrombocythemia Market Essential Thrombocythemia Market Insight, Epidemiology and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key essential thrombocythemia companies, including PharmaEssentia, Merck Sharp and Dohme, MorphoSys, Step Pharma, AOP Orphan Pharmaceuticals AG, Incyte Corporation, Janssen Research & Development, pharma&, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
